Company / Cash & Equivalents
Xtant Medical Holdings, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$17.1M
FY2025
5-year range
$5.7M / $20.3M
FY2021-FY2025
Trend
+175.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $2M in FY2020 to $20M in FY2022.
Based on SEC 10-K filings.
$17M in FY2025 with a 5-year CAGR of +48.8%.
Improved from $6M to $17M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -5.6%
- 5-Year CAGR
- +48.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +48.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 175.1% year-over-year.
- Peak cash & equivalents was recorded in FY2022.
- Lowest cash & equivalents in the period was in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.1M | +175.1% |
| FY2024 | $6.2M | +8.5% |
| FY2023 | $5.7M | -71.8% |
| FY2022 | $20.3M | +11.3% |
| FY2021 | $18.2M | +679.3% |
| FY2020 | $2.3M | -55.3% |
| FY2019 | $5.2M | +83.4% |
| FY2018 | $2.9M | +10.8% |
| FY2017 | $2.6M | -59.5% |
| FY2016 | $6.4M | +42.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026